Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
New biological treatments show promise for psoriasis
Washington - Biological treatments for psoriasis have largely unraveled the once-secret mechanisms behind this disease. "The biologics including Amevive [alefacept], Raptiva [efalizumab], Embrel [etanercept], and Remicade [infliximab] are scientifically revolutionary and exciting," said John Y. M. Koo, M.D., who spoke about these treatments at the American Academy of Dermatology meeting. Board-certified in dermatology and psychiatry, he is professor and vice chairman of the University of California at San Francisco's department of dermatology.
Related Videos
Related Content
